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A  bloodstream infection (BSI) is the most common serious infectious complication of hematopoietic 
stem cell transplantation (HSCT) [1-3].  BSI can develop 
after the start of the pre-transplant treatment and before 
the peri-engraftment period as a result of immunodefi-
ciency due to neutropenia and mucosal damage associ-
ated with the pre-transplant treatment,  and can in turn 
induce graft-versus-host disease (GVHD).  Both treat-
ment and prophylaxis for GVHD are impacted by the 
presence of BSI.
BSI promotes an inflammatory condition,  which 
exacerbates acute GVHD [4].  However,  about 10 years 
ago,  2 studies reported that a BSI is a risk factor of 
acute GVHD [1 , 5].  In recent years,  transplant sources 
and pre-transplantation treatments have widened to 
encompass cord blood (CB),  human leukocyte antigen 
(HLA)-mismatched HSCT,  and reduced-intensity stem 
cell transplantation; thus,  it is necessary to consider 
both BSI and acute GVHD after HSCT in the new era.
Regarding the mechanism by which BSI causes acute 
GVHD,  it has been proposed that lipopolysaccharides 
(LPS) produced by Gram-negative rods (GNR) contrib-
ute to the activation and expansion of donor-derived T 
cells via antigen-presenting cells,  as pathogen-associ-
ated molecular patterns (PAMPs) [4 , 6 , 7].
In this study,  we retrospectively investigated the 
cases of 465 patients who underwent allo-HSCT at a 
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A bloodstream infection (BSI) is the most common serious infectious complication of hematopoietic stem cell 
transplantation (HSCT).  BSI promotes an inflammatory state,  which exacerbates acute graft-versus-host dis-
ease (GVHD).  We investigated whether a Gram-negative rod bloodstream infection (GNR-BSI),  which devel-
ops early after allo-HSCT,  affected the onset or exacerbated acute GVHD in 465 patients who underwent allo-
HSCT from 1995 through 2015 at a single institution.  Eighty-eight patients (19%) developed BSI during the 
study period.  Among the cultures,  50 (57%) were Gram-positive cocci (GPC) and 31 (35%) were GNR.  Of the 
465 patients,  187 (40%) developed acute GVHD of grade II or higher within the first 100 days post-allogeneic 
HSCT: 124 (27%) had acute GVHD grade II,  47 (10%) had grade III,  and 16 (3%) had grade IV.  Multivariate 
analysis revealed that GNR-BSI was a significant risk factor for grade II-IV acute GVHD (grade II-IV: hazard 
ratio [HR] 1.75,  95% confidence interval [CI] 1.03-2.97; grade III-IV: HR 2.37,  95% CI 1.03-5.43).  These 
results suggest that GNR-BSI may predict the onset and exacerbation of acute GVHD.
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single institution to determine whether they developed 
GNR-BSI and,  if so,  whether GNR-BSI induced or 
exacerbated acute GVHD.
Patients and Methods
Study design and patient population. We retro-
spectively studied 523 consecutive allogeneic HSCT 
recipients whose HSCTs were performed at Okayama 
University Hospital from 1995 through 2015.  The study 
setting is shown in Fig. 1.  During HSCT,  all patients 
were isolated in a room equipped with a laminar airflow 
system and received trimethoprim-sulfamethoxazole for 
prophylaxis of Pneumocystis jirovecii.  Fluoroquinolone 
(mainly levofloxacin: 300-500 mg/day) was adminis-
tered for antibiotic prophylaxis on a case-by-case basis 
in consideration of the risk of infection and the emer-
gence of resistant bacteria.  Fluconazole (200-400 mg/
day) or micafangin (50-150 mg/day) was administered 
for prophylaxis of fungal infections.  Acyclovir (200-
1,000 mg/day) was also given as prophylaxis against 
herpes virus infection.  Neutropenic fever was managed 
according to the guidelines [8 , 9].  Granulocyte colo-
ny-stimulating factor (lenograstim 5 μg kg/day or fil-
grastim 300 μg/m2) was given intravenously for 60 min,  
starting on day 1 or 5 after HSCT,  and was continued 
until the absolute neutrophil count was > 5 × 109/L.
We analyzed the data by means of a multivariate 
analysis,  with the incidence of acute GVHD as the pri-
mary variable and the presence of GNR-BSI as the sec-
ondary variable.  We compared the incidence of acute 
GVHD between the GNR-BSI(+) and GNR-BSI(−) 
groups.  Other endpoints included the cumulative inci-
dence of GNR-BSI and total BSI,  and disease-free sur-
vival (DFS).
All data were collected retrospectively from medical 
records and entered into a database for research pur-
poses.  This study was approved by the Ethics Committee 
of Okayama University Hospital (approval number:  
1701-510).
Definitions. Neutrophil engraftment was defined 
as an absolute neutrophil count > 0.5 × 109/L for 3 con-
secutive days.  Platelet engraftment was defined as a 
platelet count > 20 × 109/L independent of transfusion.  
Primary graft failure was defined as profound,  per-
sistent pancytopenia and marrow hypoplasia without 
donor-derived cells on day 60 after HSCT,  or the 
requirement for a second allogeneic HSCT.  The diag-
nosis and grades of acute GVHD were defined by 
Glucksberg et al.  [10].
The definition of BSI was adapted from the 2004 
Centers for Disease Control and Prevention definition 
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Fig. 1　 Study setting.  In total,  523 patients underwent consecutive allogeneic HSCT during the study period.  Fifty-eight cases were 
excluded from the analysis because of engraftment failure.  Therefore,  465 cases were included in the final analysis.  Eighty-eight patients 
(19%) developed a BSI during the study period.  We analyzed the total of 34 patients with GNR-BSI,  which included 4 cases that had both 
GNR-BSI and GPC-BSI (shaded area).
SCT,  stem cell transplantation; GVHD,  graft-versus-host disease; TRM,  treatment related mortality; BSI,  blood stream infection; GNR,  
gram-negative rods; GPC,  Gram-positive cocci.
for nosocomial infection [11].  In the case of bacteria 
not known to normally colonize the skin,  such as 
Gram-negative bacilli,  or certain pathogens such as 
Staphylococcus aureus or fungi,  BSI was defined as at 
least one positive blood culture [12].  For bacteria that 
typically colonize the skin,  such as coagulase-negative 
Staphylococcus,  Propionibacterium,  the Streptococcus 
viridans group,  and non-JK strains of Corynebacterium,  
two consecutive positive blood cultures,  2 positive 
blood cultures within 72 h,  or one positive blood cul-
ture and one positive intravascular catheter tip culture 
within 72 h constituted a BSI.  All blood cultures were 
obtained in response to an indication of infection,  usu-
ally fever (armpit temperature ≥ 37.5°C).
Statistical analysis. The results are presented as 
median values with ranges.  The probabilities of acute 
GVHD,  incidence of BSI by donor sources,  and DFS 
rates were estimated using the Kaplan-Meier method,  
and the significance of differences among the curves was 
evaluated with prognostic factors on DFS.  We used Cox 
regression proportional hazard analysis to assess the risk 
factors for grade II to IV or grade III to IV acute 
GVHD.  The variables analyzed in this model were 
GNR-BSI,  age (> 55 years vs. ≤ 54 years),  donor type 
(BM,  PB,  CB,  or Haplo),  risk level (non-remission or 
second SCT),  HLA category (> 2 vs. ≤ 1 locus mis-
match),  conditioning (myeloablative vs. non-myeloab-
lative),  antimicrobial prophylaxis,  and diseases.  These 
variables were selected because they were gatherable 
among the factors that could be involved in the devel-
opment of BSI and acute GVHD in this retrospective 
setting.  The chi-square test was performed to compare 
the proportions between two or more groups.  A p-value 
< 0.05 was considered significant.  All statistical analyses 
were performed using SPSS software (v. 23.0; IBM Corp,  
Armonk,  NY,  USA).
Results
Patient characteristics. In total,  523 patients 
underwent consecutive allogeneic HSCT during the 
study period.  Fifty-eight cases were excluded from the 
analysis because of engraftment failure.  Therefore,  data 
on 465 cases were entered into the final analysis (Fig. 1).  
Their characteristics are shown in Table 1.  The median 
age of all patients was 50 years (range: 15-73 years).  
The major underlying disease was acute myeloid leuke-
mia in 169 cases (36%),  myelodysplastic syndrome in 
70 cases (15%),  acute lymphoblastic leukemia in 70 
cases (15%),  and malignant lymphoma in 105 cases 
(23%).  The high-risk allogeneic HSCT group included 
165 cases (36%) of non-remission.  No significant dif-
ferences in characteristics were observed between the 
BSI and non-BSI groups.
Allogeneic sources of stem cells included bone mar-
row (BM) in 193 cases (42%),  peripheral blood (PB) 
stem cells including haploidentical (Haplo) donors in 
187 cases (40%),  and umbilical CB in 85 cases (18%).  A 
myeloablative conditioning regimen was administered 
in 237 cases (51%),  and a reduced-intensity condition-
ing or non-myeloablative conditioning regimen was 
administered in 228 cases (49%).  In the majority of 
patients,  acute GVHD prophylaxis consisted of cyclo-
sporine + methotrexate (206 cases,  45%) or tacrolimus 
+ methotrexate (163 cases,  35%).  A total of 334 cases 
(72%) received antimicrobial prophylaxis.  A significant 
difference in antimicrobial prophylaxis was observed 
between the BSI and non-BSI groups (p = 0.001).
Bacterial BSI. Eighty-eight patients (19%) devel-
oped a BSI during the study period (Table 2).  BSI was 
defined to exclude contamination as described in the 
Patients and Methods section.  Median onsets of both 
total and GNR-BSI were 6 days (range: 4-336 days) 
after HSCT.  In total,  97 blood isolates were obtained 
from the BSI episodes of the 88 individuals.  Among 
these cultures,  50 (57%) were Gram-positive cocci 
(GPC).  Of the GPC,  50% (or 28% of the total number 
of isolates) were Staphylococcus epidermidis ; 35% 
(n = 31) were GNR.  Of the GNR,  32% (or 11% of the 
total number of isolates) were Escherichia coli.  Moreover,  
GNR was detected as the second BSI in 3 patients.  On 
the other hand,  one patient developed GPC-BSI after 
the occurrence of GNR-BSI.  A second BSI was defined 
as BSI developing after the initial BSI was clinically 
recovered.  We analyzed a total of 34 patients with 
GNR-BSI,  which included 4 cases that had both GNR-
BSI and GPC-BSI (Fig. 1,  shaded area).
In the overall BSI group,  CB and Haplo donors were 
the most common donor sources (cumulative inci-
dence: CB,  28.0%; Haplo,  24.5%; BM,  17.4%; PB,  
13.5%: CB vs. PB,  p = 0.015).  The same tendency was 
seen in the GNR-BSI group (cumulative incidence:  
Haplo,  14.0%; CB,  11.3%; BM,  5.9%; PB,  5.7%:  
Haplo vs. BM,  p = 0.043).
The median follow-up time of this study was 272 
days (range: 10-7,223 days).  The 5-year DFS rate was 
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significantly higher in the non-BSI group than the over-
all BSI group (42.5% vs. 28.7%,  p = 0.006,  Fig. 2A).  The 
5-year DFS rate was significantly higher in the non-
GNR-BSI group than the GNR-BSI group (41.5% vs. 
18.9%,  p = 0.002,  Fig. 2B).
Acute GVHD. Of the 465 patients,  187 (40%) 
developed acute GVHD of grade II or higher post-allo-
geneic HSCT: 124 (27%) had grade II,  47 (10%) had 
grade III,  and 16 (3%) had grade IV.  The median times 
to development of grade II to IV and grade III to IV 
acute GVHD were 30 days (range 7-144) and 29 days 
(range 11-144),  respectively.  Of the 88 patients who 
developed BSI,  48 patients went on to develop acute 
GVHD; among the 48 patients with acute GVHD,  the 
median BSI onset was day 6 after HSCT (range: 4-72) 
and the median acute GVHD onset was day 30 after 
HSCT (range: 11-121).
BSI and acute GVHD of grade II or higher. A 
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Table 1　 Patient characteristics













Median 50 49 50 47.5 50
Range 15-73 19-72 15-73 19-66 15-73
Sex (%)
Male 279 (60) 57 (65) 222 (59)
0.310
23 (68) 256 (59)
0.344Female 186 (40) 31 (35) 155 (41) 11 (32) 175 (41)
Disease (%)
Acute myeloid leukemia 169 (36) 42 (48) 127 (34)
0.122
16 (47) 153 (35)
0.835
Myelodysplastic syndromes 70 (15) 9 (10) 61 (16) 5 (15) 65 (15)
Acute lymphoblastic leukemia 70 (15) 9 (10) 61 (16) 4 (12) 66 (15)
Malignant lymphoma 105 (23) 19 (22) 86 (23) 6 (18) 99 (23)
Multiple myeloma 5 (1) 2 (2) 3 (1) 1 (3) 4 (1)
Myeloproliferative neoplasms 19 (4) 1 (1) 18 (5) 0 (0) 19 (4)
Aplastic anemia 16 (3) 5 (6) 11 (3) 2 (6) 14 (3)
Solid tumors 8 (2) 0 (0) 8 (2) 0 (0) 8 (2)
Other 3 (1) 1 (1) 2 (1) 0 (0) 3 (1)
High risk (%) Non-remission 165 (35) 32 (36) 133 (35) 0.874 13 (38) 152 (35) 0.742
Donor Source 
(%)
Bone marrow 193 (42) 34 (39) 159 (42)
0.116
11 (32) 182 (42)
0.228
Peripheral blood 144 (31) 21 (24) 123 (33) 9 (26) 135 (31)
Cord blood 85 (18) 22 (25) 63 (17) 8 (24) 77 (18)
Haplo-identical 43 (9) 11 (13) 32 (8) 6 (18) 37 (9)
Cycle (%) ≧2nd 76 (16) 19 (22) 57 (15) 0.139 9 (26) 67 (16) 0.097
HLA (%) ≧2/6 mismatch 90 (19) 23 (26) 67 (18) 0.074 8 (24) 82 (19) 0.522
Conditioning 
(%)
MAC 237 (51) 43 (49) 194 (51)
0.661
14 (41) 223 (52)
0.236RIC/NMA 228 (49) 45 (51) 183 (49) 20 (59) 208 (48)
Pre-antibacterial agents (%) 334 (72) 51 (58) 283 (75) 0.001 16 (47) 318 (74) 0.001
GVHD
prophylaxis
CSP+MTX 206 (44) 40 (45) 166 (44)
0.949
15 (44) 191 (44)
0.851
CSP+MMF 27 (6) 4 (5) 23 (6) 0 (0) 27 (6)
CSP+mPSL 7 (2) 2 (2) 5 (1) 1 (3) 6 (1)
TCR+MTX 163 (35) 29 (33) 134 (36) 11 (32) 152 (35)
TCR+MMF 15 (3) 2 (2) 13 (3) 1 (3) 14 (3)
TCR+mPSL 39 (8) 11 (13) 28 (7) 6 (18) 33 (8)
Other 8 (2) 0 (0) 8 (2) 0 (0) 8 (2)
HLA,  human leukocyte antigen; GVHD,  graft-versus-host disease; BSI,  blood stream infection; GNR,  gram-negative rods; MAC,  mye-
loablative conditioning; RIC,  reduced-intensity conditioning; NMA,  non-myeloablative conditioning; CSP,  cyclosporin; MTX,  methotrex-
ate; MMF,  mycophenolate mofetil; mPSL,  methylprednisolone; TCR,  tacrolimus.
BSI occurring before acute GVHD was the primary 
predictor of interest.  Thus,  patients with BSI that 
occurred after acute GVHD of grade II or higher were 
censored,  and only BSIs that occurred before acute 
GVHD of grade II or higher were assessed.
We visualized the relationship between BSI and 
acute GVHD of grade II or higher via a Kaplan-Meier 
analysis (Fig. 3).  The cumulative incidence rates of 
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Table 2　 Etiology of blood stream infection
1st BSI 2nd BSI
Etiology of BSI N % N % Resistant N %
GNR
Escherichia coli 10 11.4 1 1.1
Enterobacter spp. 3 3.4 0 0.0
Klebsiela pneumoniae 7 8.0 0 0.0 ESBL 1 1.1
Pseudomonas aeruginosa 6 6.8 2 2.3 MDRP 0 0.0
Stenotrophomonas maltophillia 2 2.3 2 2.3
　Other GNR 3 3.4 0 0.0
Total GNR 31 35.2 5 5.7
GPC
Staphylococcas aureus 4 4.5 1 1.1 MRSA 5 4.5
Staphylococcus epidermidis 25 28.4 2 2.3 MRCNS 3 3.4
　Other staphylococcus spp. 4 4.5 0 0.0
Streptococcus spp. 7 8.0 0 0.0
Enterococcus spp. 9 10.2 1 1.1
　Other GPC 1 1.1 0 0.0
Total GPC 50 56.8 4 4.5
GPR
Bacillus spp. 4 4.5 0 0.0
Corynebacterium spp. 2 2.3 0 0.0
Listeria spp. 1 1.1 0 0.0
Total GPR 7 8.0 0 0.0
BSI,  blood stream infection; GNR,  gram-negative rods; GPC,  gram-positive cocci; ESBL,  extended spectrum β-lactamases; MDRP,  
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Fig. 2　 The 5-year disease-free 
survival according to the blood 
stream infection.  The 5-year DFS 
rate was significantly higher in the 
non-BSI group than the overall BSI 
group (42 .5% vs. 28 .7%,  
p=0.006,  Figure 2A).  The 5-year 
DFS rate was significantly higher 
in the non-GNR-BSI group than the 
GNR-BSI group (41.5% vs. 18.9%,  
p=0.002,  Figure 2B).  The DFS 
rate was estimated using the 
Kaplan-Meier method,  and the 
significance of differences among 
the curves was evaluated with the 
log rank test.
BSI,  blood stream infection;  
DFS,  disease-free survival; GNR,  
gram-negative rods.
acute GVHD of grade II or higher in the non-BSI and 
BSI groups were 41.1% and 47.5%,  respectively 
(p = 0.516,  Fig. 3A).  The cumulative incidence rates of 
acute GVHD of grade II or higher in the non-GNR-BSI 
group and the GNR-BSI group were 40.8% and 63.8%,  
respectively,  which represented a trend towards signifi-
cance (p = 0.067,  Fig. 3B).
The multivariate analysis revealed that GNR-BSI and 
BM as a stem cell source were significant risk factors for 
acute GVHD of grade II or higher (GNR-BSI: hazard 
ratio [HR] 1.75,  95% confidence interval [CI] 1.03-2.97,  
p = 0.037; BM as a stem cell source: HR 1.50,  95% CI 
1.04-2.17; Table 3).
BSI and acute GVHD of grade III or higher. We 
visualized the relationship between BSI and acute 
GVHD of grade III or higher i.e.,  severe acute GVHD) 
via a Kaplan-Meier analysis (Fig. 4).  The cumulative 
incidence rates of acute GVHD of grade III or higher in 
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Table 3　 Multivariate analysis of risk factors for grade II-IV acute GVHD
Variable Hazard ratio [95% CI] P value
GNR-BSI 1.75 [1.03-2.97] 0.037
Age (>55 years vs. ≤54 years) 0.99 [0.71-1.40] 0.969
Donor type
　　　Peripheral blood 1.00 [reference] 0.117
　　　Bone marrow 1.50 [1.04-2.17] 0.029
　　　Cord blood 0.94 [0.49-1.80] 0.861
　　　Haplo-identical 0.88 [0.35-2.25] 0.793
Risk level (non-remission or 2nd HSCT) 1.23 [0.89-1.70] 0.207
HLA category (>2 vs. ≤1 locus mismatch) 0.80 [0.39-1.64] 0.549
Conditioning (myeloablative vs. non-myeloablative) 0.99 [0.69-1.40] 0.935
Antimicrobial prophylaxis 0.99 [0.69-1.44] 0.963
Disease
　　　Solid tumor 1.00 [reference] 0.481
　　　Acute myeloid leukemia 2.06 [0.48-8.77] 0.330
　　　Myelodysplastic syndromes 1.81 [0.42-7.89] 0.429
　　　Acute lymphoblastic leukemia 1.60 [0.36-7.09] 0.533
　　　Malignant lymphoma 1.93 [0.45-8.19] 0.374
　　　Myeloproliferative neoplasms 4.39 [0.88-21.35] 0.071
　　　Aplastic anemia 0.97 [0.17-5.57] 0.975
CI,  confidence interval; GNR,  gram-negative rods; BSI,  blood stream infection; HSCT,  hematopoietic stem cell transplantation; HLA,  
human leukocyte antigen.
Fig. 3　 Cumulative incidence of 
grade II or higher acute GVHD 
according to the blood stream 
infection.  Cumulative incidence of 
acute GVHD of grade II or higher 
in the non-BSI and BSI groups (A) 
and the non-GNR-BSI and GNR-
BSI groups (B).  Cumulative inci-
dence was estimated using the 
Kaplan-Meier method and the 
significance of differences among 
the curves was evaluated with the 
log rank test.
BSI,  blood stream infection;  
GVHD,  graft-versus-host disease;  
GNR,  gram-negative rods.
the non-BSI and BSI groups were 12.9% and 19.2%,  
respectively (p = 0.185,  Fig. 4A).  The cumulative inci-
dence rates of acute GVHD of grade III or higher in the 
non-GNR-BSI and GNR-BSI groups were 13.1% and 
27.1%,  respectively (p = 0.035,  Fig. 4B).
The multivariate analysis revealed that only GNR-
BSI was a significant risk factor for acute GVHD of 
grade III or higher (HR 2.37,  95% CI 1.03-5.43,  
p = 0.041; Table 4).
Discussion
The present study revealed that GNR-BSI was a sig-
nificant risk factor for grade II-IV acute GVHD in a 
multivariate analysis.
Acute GVHD is a well-known risk factor for 
post-transplant infection; however,  few clinical studies 
have investigated the effect of BSI on the development 
of acute GVHD.  Poustsiaka et al.  reported that early BSI 
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Table 4　 Multivariate analysis of risk factors for grade III-IV acute GVHD
Variable Hazard ratio [95% CI] P value
GNR-BSI 2.37 [1.03-5.43] 0.041
Age (>55 years vs. ≤54 years) 0.85 [0.47-1.56] 0.601
Donor type
　　　Peripheral blood 1.00 [reference] 0.990
　　　Bone marrow 1.11 [0.56-2.20] 0.773
　　　Cord blood 1.12 [0.39-3.27] 0.830
　　　Haplo-identical 1.20 [0.28-5.07] 0.806
Risk level (non-remission or 2nd HSCT) 1.56 [0.88-2.77] 0.132
HLA category (>2 vs. ≤1 locus mismatch) 0.59 [0.19-1.82] 0.362
Conditioning (myeloablative vs. non-myeloablative) 1.05 [0.56-1.98] 0.875
Antimicrobial prophylaxis 0.80 [0.40-1.58] 0.516
Disease
　　　Solid tumor 1.00 [reference] 0.988
　　　Acute myeloid leukemia 0.86 [0.10-7.01] 0.884
　　　Myelodysplastic syndromes 0.99 [0.12-8.42] 0.989
　　　Acute lymphoblastic leukemia 0.86 [0.10-7.51] 0.889
　　　Malignant lymphoma 1.11 [0.14-8.94] 0.919
　　　Myeloproliferative neoplasms 2.37 [0.22-25.62] 0.477
　　　Aplastic anemia 0.53 [0.03-9.26] 0.666
CI,  confidence interval; GNR,  gram-negative rods; BSI,  blood stream infection; HLA,  human leukocyte antigen.
Fig. 4　 Cumulative incidence of 
grade III or higher acute GVHD 
according to the blood stream 
infection.  Cumulative incidence of 
acute GVHD of grade II or higher 
in the non-BSI and BSI groups (A) 
and non-GNR-BSI and GNR-BSI 
groups (B).  Cumulative incidence 
was estimated using the Kaplan-
Meier method and the significance 
of differences among the curves 
was evaluated with the log rank 
test.
BSI,  blood stream infection;  
GVHD,  graft-versus-host disease;  
GNR,  gram-negative rods.
was independently associated with an increased risk of 
subsequent grade II-IV acute GVHD [13].  Their report 
was published in 2011,  and 93% of patients were trans-
planted from 6/6 HLA-matched donors.  In contrast,  
19% of our patients were transplanted from donors 
mismatched for ≥ 2 HLA loci (Haplo or CB donors).  
Nonetheless,  despite differences in the era and donor 
sources between the previous study and our investiga-
tion,  both studies found an association between BSI and 
acute GVHD.
Our results indicated that GNR-BSI was more 
strongly associated with severe acute GVHD and DFS 
than the other types of BSI.  Both exogenous and 
endogenous “danger signal proteins” are released from 
damaged tissues and abnormal intestinal microbial col-
onies after conditioning.  In addition,  BSI caused by gut 
translocation of colonized bacteria is another critical 
source of PAMPs after allo-HSCT [13].  Experimental 
data showed that PAMP and damage-associated molec-
ular pattern proteins can function either independently 
or synergistically to initiate GVHD [14].  The putative 
mechanism of acute GVHD after BSI is that LPS pro-
duced by GNR promotes activation of dendritic cells as 
PAMPs [4 , 6 , 7].  In the activation of immune cells 
through a complex signaling cascade,  toll-like receptors 
(TLRs) play an important role in recognizing PAMPs 
[15].  In addition to TLRs,  various nucleotide-binding 
and oligomerization domain (NOD)-like receptors are 
essential for the recognition of PAMPs,  and have the 
ability to initiate and support robust immune responses 
through the formation of inflammasomes and the acti-
vation of nuclear factor-kappa B,  interferon regulatory 
factor,  and mitogen-activated protein kinase pathways 
[16].  However,  a child and adolescent study suggested 
that only a mucosal barrier injury associated with BSI is 
related to severe acute GVHD [17].  Kameda et al.  
showed that while BSI is not a significant risk factor for 
grade II-IV acute GVHD,  early febrile neutropenia 
after HSCT may be a risk factor [18].  Although further 
investigation is needed,  this is nevertheless the first 
study to demonstrate an association between GNR-BSI 
and acute GVHD.
The microbiological spectrum of the BSI cases in our 
study accords with the literature,  with Gram-positive 
bacteria being predominantly involved [1-3 , 19 , 20].  
Bacterial invasion,  such as by Enterococcus spp.,  of skin 
flora due to long-term placement of a catheter or a BSI 
in the intestinal tract,  is often the cause of infection.  
Our study showed that S. epidermidis was a highly prev-
alent Gram-positive bacterium,  but as only cases con-
firmed twice were treated,  the likelihood of contamina-
tion was low,  suggesting the possibility of catheter- 
related BSI.
In this study,  CB and Haplo donors tended to be 
more strongly associated with total BSI and GNR-BSI.  
We speculate that CB transplantation results in more 
long-term cytopenia compared to other donor sources;  
patients in the present series who underwent Haplo 
transplantation were more likely to have infections or 
re-transplantations,  resulting in a higher incidence of 
BSI.  Consequently,  the 5-year DFS was significantly 
shorter in both the total BSI and GNR-BSI groups.
Our study showed that antibiotic prophylaxis was 
more prevalent in the non-BSI group than the BSI 
group.  Although antimicrobial prophylaxis has been 
suggested to reduce the incidence of BSI,  our multivar-
iate analysis showed that it did not reduce the rate of 
acute GVHD.  This might have been related to the small 
number of non-antimicrobial prophylaxis cases.  
Further study is needed to clarify whether antibiotic 
prophylaxis reduces BSIs,  and thus the likelihood of 
acute GVHD.
Engelhard et al.  reported recommendations for the 
prevention of bacterial infection after hematopoietic cell 
transplantation [21].  They considered that patients with 
severe hypogammaglobulinemia (that is,  IgG < 400 mg 
per 100 mL) may be indicated for intravenous immu-
noglobulin prophylaxis.
Several limitations of this study should be discussed.  
First,  this was a single-center,  retrospective analysis.  
We could not analyze the relationship among the onset 
of BSI,  duration and dose of GVHD prophylaxis and 
acute GVHD.  In addition,  there may have been biases 
due to a variety of uncontrolled factors,  such as under-
lying disease.  There may also have been a study bias 
related to progress in this field,  such as improvements 
in GVHD prophylaxis and the diagnostic sensitivity of 
sepsis.  Moreover,  patients who died during the pre- 
engraftment period were excluded from the study 
because acute GVHD could not be assessed.  In general,  
cases of pre-engraftment mortality usually develop BSI.  
Although additional analyses were performed on all 523 
allo-HSCT patients with presymptomatic death due to 
acute GVHD,  sufficiently powered analyses could not 
be performed (data not shown).  Finally,  our study 
included four cases who developed both GPC-BSI and 
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GNR-BSI.  In such cases,  GNR may not be a direct fac-
tor in acute GVHD and should be interpreted with 
caution.  In future studies,  it will be necessary to include 
more cases.
In conclusion,  GNR-BSI was a significant risk factor 
for grade II or higher acute GVHD in a multivariate 
analysis.  The findings of this study may help in predict-
ing the onset and exacerbation of acute GVHD.  In the 
future,  a larger analysis of registry data will be needed 
to clarify the relationship between these two serious 
complications in the hope of improving the outcomes of 
allo-HSCT.
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